7 documents found, page 1 of 1

Clinical Outcomes of Chemo-Immunotherapy for Extensive Stage Small Cell Lung Ca...

Small cell lung cancer (SCLC) is an aggressive type of lung cancer. Recent studies have provided a new hope by adding atezolizumab to the standard treatment of extensive disease SCLC (E-SCLC). The aim of our study was to evaluate the real-life performance of atezolizumab plus chemotherapy in extensive stage SCLC in a Portuguese setting. Data was collected on twenty patients (70% were male with a mean age of 66....

Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small...

First-line therapy for metastatic non-small-cell lung cancer without targetable mutations is platinum-based chemotherapy plus pembrolizumab if programmed death ligand 1 is < 50%. The aim of this real-life retrospective study is to assess the efficacy and safety of this therapy. This retrospective observational study was conducted at the Pulmonary Oncology Department in Unidade Local de Saúde Santa Maria, in ...

Immunotherapy in lung cancer brain metastases

Brain metastases (BM) occur frequently in lung cancer, particularly in non-small cell lung cancer (NSCLC) patients and remain a significant cause of morbidity and mortality. Standard therapies have limited efficacy due to poor crossing of the blood-brain barrier and the distinct features between BM and the primary tumor. This review explores the immune landscape of brain metastatic disease, emerging immunothera...

Long-term Follow-up of Resected EGFR-mutated Non-small Cell Lung Cancer: A Real...

Surgically resected epidermal growth factor receptor-mutated non-small cell lung cancer continues to carry a substantial risk of recurrence. The aim of this retrospective, single-center study, conducted at a Portuguese tertiary hospital was to evaluate the clinical course of these patients, diagnosed between 2016 and 2020, with the final clinical data review in November, 2024. A total of 48 patients were includ...

Solitary Fibrous Tumors of the Chest: Case Series from a Portuguese Center

The solitary fibrous tumor is a rare mesenchymal tumor with predilection for the pleura. Most times it is an incidental diagnosis. Surgery is the recommended treatment. Most solitary fibrous tumors (SFTs) exhibit indolent behavior; however, 10% to 25% may experience recurrence. The aim of this retrospective analysis is to characterize their presentation, therapeutic approach and recurrence and was conducted at ...

Real-world challenges in first-line treatment of metastatic EGFR-mutated non-sm...

Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), was recently introduced in several countries, including Portugal (reimbursement in 2021), as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating proto-oncogene epidermal growth factor receptor mutations (EGFRm), after showing significant efficacy and safety when used in patients ...

Real-world challenges in first-line treatment of metastatic EGFR-mutated non-sm...